Division of Silence Therapeutics PLC
Latest From Intradigm Corp.
The 2011 Nobel Prize in Medicine was awarded on 3 October to Bruce Beutler and Jules Hoffmann for discoveries in innate immunity, and to Ralph Steinman for his discovery of the dendritic cell and its role in adaptive immunity. While the headline news is that Steinman's award will proceed even though he died (on 30 September) without knowing of the prize, the timing of the award can serve to remind those in the life sciences that good science – even Nobel-quality science – is not a surrogate for or predictor of subsequent commercial success.
Silence Therapeutics' shares opened at 12.5 pence on 7 September, up 75% on the previous day's opening price, after the company announced that it had been approached by an undisclosed company.
AstraZeneca and Silence Therapeutics have signed a one-year extension to their R&D collaboration covering siRNA molecules.
AstraZeneca and Silence Therapeutics have agreed a one-year extension to their ongoing small interfering RNA (siRNA) delivery collaboration.
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Silence Therapeutics PLC
- Senior Management
- Xiao-Dong Yang, MD, PhD, VP, Research & Preclin. Dev.
- Contact Info
Phone: (650) 855-9696
3350 W. Bayshore Rd.
Palo Alto, CA 94303
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.